Key Highlights
- SELLAS Life Sciences (NASDAQ:SLS) shed 13.98% on November 19, 2026, the session after a proposed USD 150.0 million offering, which carries an extra USD 22.5 million that underwriters may place within 30 days.
- PepGen (NASDAQ:PEPG) advanced 8.82% notwithstanding a Placement of USD 125 million at USD 5.00 per share, executed on November 11, 2026, leaving the share price roughly 16.8% lower than that figure (calculated).
- ARS Pharmaceuticals (NASDAQ:SPRY) retreated 7.62% without a catalyst identified; the third-quarter net loss reached USD 35.6 million, and cash has dropped close to USD 107 million since the December 31, 2025 date (calculated).
- Evolent Health (NYSE:EVH) fell 5.47% as its medical expense ratio for the third quarter rose from 85.0% to 93.0%, cutting adjusted EBITDA Margin from 8.1% to 4.7%.
SELLAS Life Sciences (NASDAQ:SLS): Equity Sale Follows Positive Trial Readout
Its shares were the weakest in the group despite recent favourable trial news. Phase 3 REGAL, testing galinpepimut-S in acute myeloid leukemia, met its overall survival endpoint, the company disclosed on November 17, 2026. Patients lived a median of 24.0 months, while the best-available-therapy control arm managed 14.7 months. Soon after, SELLAS began an underwritten public offering for USD 150.0 million, with underwriters entitled to an extra USD 22.5 million over a 30-day window. Every offered share is newly issued by the company, and J.P. Morgan and TD Cowen are the joint bookrunners under a shelf registration made on March 20, 2026. The release carried no price, so the discount to the last trade cannot be measured, and the planned use of funds was not disclosed. Deals of this kind commonly price below market to clear the block, which tends to pressure the stock. Relative to market value, the raise equals roughly 4% (calculated, before new shares). The trial was open-label and enrolled 126 patients, regulators may seek more data, and the raise's timing and terms are not guaranteed. A small number of trades can move the shares sharply.
PepGen (NASDAQ:PEPG): Share Gain Sits Under the Offering Price
PepGen (NASDAQ:PEPG) was the only name in the set to finish higher, rising 8.82%, yet the figure leaves it under the price paid by investors in its recent placement. On November 11, 2026 the company issued 25 million new shares at USD 5.00, anticipating USD 125 million gross, one day after disclosing Phase 2 findings for the PGN-EDODM1 candidate aimed at myotonic dystrophy type 1. The 10 mg/kg cohort achieved average splicing correction of 46.5%, and no serious adverse events were recorded. Company-specific news from the days preceding this session could not be located, so the rise lacks a verified cause and may reflect a rebound. Cash was USD 104.8 million on September 30, 2026, and the gross proceeds would bring the total to around USD 229.8 million before fees (calculated). Quarterly net loss, third quarter, came in at USD 19.4 million. A partial clinical hold imposed by the FDA in March 2026 is the most important risk, and it can also affect the schedule of regulatory discussions. The placement dilutes current shareholders, and low-priced stocks can reverse abruptly. Underwriters possess an option on as many as 3.75 million extra shares, and closing has not been confirmed. Before the raise, management had indicated cash would last into 2028, so the new Capital mostly extends the window for the next trial cohort.
ARS Pharmaceuticals (NASDAQ:SPRY): Gradual Erosion Linked to Spending
No corporate announcement, regulatory filing or analyst action emerged in recent days to account for the 7.62% decline, so no cause is assigned here. The latest material release was the third-quarter report from November 5, 2026. Revenue advanced to USD 37.7 million, up from USD 32.5 million in the prior-year period. U.S. net product revenue for the needle-free epinephrine spray neffy reached USD 33.4 million, roughly 6.7% higher (calculated). Management said end-user Demand grew faster and linked the gap to inventory moves within the channel. The loss narrowed to USD 35.6 million, reflecting lower selling costs after the broad consumer Marketing campaign was discontinued. Cash and short-term holdings totaled USD 138.4 million, versus about USD 245.0 million at the close of 2025. Management is targeting cash-flow breakeven by the end of 2027. One published account suggested term-loan Debt near USD 121.8 million; because only one source reported it, that figure is unconfirmed here. The principal worry is funding: any miss on the breakeven objective would make new capital more likely, and light trading in a low-priced name can exaggerate price changes.
Evolent Health (NYSE:EVH): Medical Cost Ratio Outpaces Sales Growth
Evolent Health (NYSE:EVH) lost 5.47%, the gentlest decline among the four, and there was again no company announcement covering the move. The most recent confirmed event is the quarterly release dated November 5, 2026. Revenue expanded to USD 725.4 million, compared with USD 479.5 million, but adjusted EBITDA fell to USD 34.3 million from USD 39.0 million. Medical costs paid under risk-based contracts, measured against revenue, form the medical expense ratio, which moved from 85.0% to 93.0%. Management raised the 2026 adjusted EBITDA range to a band of USD 130.0 million to USD 135.0 million, and kept the revenue range at USD 2.6 billion to USD 2.7 billion. Medical claims, rather than share issuance, drive the pressure. Cash of USD 148.3 million is held against net long-term debt of USD 969.5 million, which implies net debt of about USD 821.2 million (calculated). Up to USD 50 million is planned for debt reduction before year-end. Seven renewals and new revenue arrangements this year improve visibility, though converting contract wins into margin takes time. The main risks are leverage, medical cost trends and the speed of that margin conversion.
Where Things Stand
Two of the four moves follow capital raising, while the other two track cash burn and medical costs, so the spread reflects separate forces. SELLAS Life Sciences (NASDAQ:SLS) fell 13.98% after its USD 150.0 million equity deal, the sharpest decline in the group. PepGen (NASDAQ:PEPG) rose 8.82% even though its placement was struck at USD 5.00 per share. ARS Pharmaceuticals (NASDAQ:SPRY) has no catalyst identified and is consuming cash, and Evolent Health (NYSE:EVH) likewise lacks a catalyst while facing margin strain. Upcoming checkpoints include SELLAS pricing, the PepGen offering's closing and hold status, the first-quarter 2027 ARS-2 readout, and Evolent's debt reduction and fourth-quarter report. None of these checkpoints guarantees a direction for the shares.






Please wait processing your request...